CARIBOU BIOSCIENCES INC. - COMMON STOCK

Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024

25 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML

03 9 2024 07:01:11 提供 Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

26 8 2024 15:00:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

12 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

06 8 2024 15:05:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

09 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

02 6 2024 18:00:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

30 5 2024 15:01:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

07 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

01 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 4 2024 09:00:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

15 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

04 4 2024 15:00:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

11 3 2024 15:05:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

05 3 2024 15:30:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

15 2 2024 15:05:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

07 1 2024 10:00:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

12 12 2023 15:02:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

07 11 2023 15:00:00 提供 Nasdaq GlobeNewswire

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

06 11 2023 07:00:00 提供 Nasdaq GlobeNewswire